Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00427050
Status:
COMPLETED
Last Update Posted:
2015-09-14
First Post:
2007-01-24
Brief Title:
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Sponsor:
Peplin
Organization:
Peplin
Study Overview
Official Title:
An Open-label Multi-centre Dose-escalation Cohort Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel When Applied to a 25 cm2 Contiguous Actinic Keratoses Treatment Area on the Face or Face and Scalp
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp
Detailed Description:
Actinic keratoses AK is a common skin condition characterized by rough scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer Current treatments can cause scarring and hypopigmentation be inconvenient or require long treatment duration Non-invasive alternative therapy for treatment of AK lesions is thus being researched
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None